Lercanidipin Sandoz

Lercanidipine hydrochloride, the active ingredient in Lercanidipin Sandoz, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercanidipin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine acts on the vascular smooth‑muscle calcium channels to lower blood pressure in hypertensive patients. - Essential hypertension: reduces systolic and diastolic blood pressure by arterial vasodilation. - Primary hypertension: improves blood pressure control when used as monotherapy or in combination. - Secondary hypertension: assists in managing elevated pressure due to identifiable causes when other treatments are insufficient.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: warmth and redness of the skin, typically on the face or neck. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially when standing quickly. - Fatigue: general feeling of tiredness without exertion. - Tachycardia: increased heart rate, usually mild.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe bradycardia: markedly slow heart rate. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lercanidipine, several safety considerations should be reviewed. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; liver disease may alter drug metabolism. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Elderly patients: increased susceptibility to orthostatic hypotension; start at low dose. - Pregnancy: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia or AV‑block. - Diuretics: can increase risk of electrolyte imbalance and orthostatic hypotension. - ACE inhibitors or ARBs: monitor renal function and potassium levels.